Abbvie Inc.

Abbott Laboratories Corporation

The Walter and Eliza Hall Institute of Medical Research

Genentech, Inc.

Abbvie Bahamas Limited

Aaron R Kunzer

Xilu Wang

Michael D Wendt

Milan Bruncko

Steven Elmore

Hong Ding

Xiaohong Song

Andrew J Souers

Zhi-Fu Tao

Gerard M Sullivan

Cheol-Min Park

William J McClellan

Le Wang

George A Doherty

Laura A Hexamer

Andrew M Petros

Lisa A Hasvold

Todd M Hansen

Christopher L Lynch

Gary T Wang

Andrew S Judd

Robert A Mantei

Robin R Frey

Noah Tu

David J Madar

Alexander R Shoemaker

Chang H Park

Thorsten K Oost

Wang Shen

David John Augeri

Stephen W Fesik

Saul H Rosenberg

Daniel A Dickman

Sheela A Thomas

Jurgen Dinges

Philip J Hajduk

Thomas Dale Penning

Daryl Richard Sauer

Yujia Dai

Chunqiu Lai

Dennie S Welch

Guillaume Laurent Lessene

Erwin R Boghaert

Steven W Elmore

Xiahong Song

Michael J Mitten

Steven A Baumeister

Cheol Min Park

David Madar

David G Nettesheim

Andrew Souers

Robin Frey

Andrew Judd

William Mcclellan

Milan Brunko

Anthony Mastracchio

Peter Colman

Peter Edward Czabotar

Cheng Ji

Chaohong Sun

David D Nettesheim

Violeta L Marin

Michael Wendt

Laura Hexamer

Lisa Hasvold

Andrew Petros

William J Mccellan

Peter Malcom Colman

George Doherty

William J Mcclellan

Thorsten Oost

Scott L Ackler

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

The present disclosure provides for compounds of formula (I) wherein A, A, A, A, A, A, A, R, R, R, R, R, R, R, R, R, R, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Macrocyclic MCL-1 inhibitors and methods of use

Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds. One embodiment of such compounds is 4-(4-{[2-(4-chloro-2-fluorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide.

Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases

Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases

Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed.

7-substituted indole Mcl-1 inhibitors

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

Growing community of inventors

Arlington Heights, IL, United States of America

Aaron R Kunzer